
During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.

During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.

Ongoing phase 3 research will help clarify the long-term benefit of amivantamab in head and neck squamous cell carcinoma.

iSCIB1+ advances toward a global phase 3 trial in advanced melanoma, with closer guidance from the FDA.

The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.

FDA approval of pimicotinib adds another CSF1R inhibitor for tenosynovial giant cell tumor, says Andrew J. Wagner, MD, PhD, of Dana-Farber Cancer Institute.

The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.

During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.

The designation supports development of elticertinib for patients with EGFR exon 20 insertion–mutated NSCLC progressing after platinum-based chemotherapy and amivantamab.

Updated THIO-101 data showed an 88% DCR with ateganosine followed by cemiplimab in third-line NSCLC after immunotherapy and chemotherapy.

Galinpepimut-S maintenance improved median OS to 24.0 vs 14.7 months with best available treatment in AML in second remission, a 41% reduction in risk of death.

The FDA accepted a supplemental application for selinexor plus ruxolitinib in myelofibrosis, setting a June 28, 2027, target action date based on phase 3 SENTRY findings.

The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.

The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.

Andrew Aguirre, MD, PhD, explained how daraxonrasib, a molecular glue RAS inhibitor, nearly doubled overall survival in previously treated pancreatic cancer.

Final PECATI results show a median PFS of 22.1 months and median OS of 40.2 months with lenvatinib plus pembrolizumab in pretreated B3 thymoma and thymic carcinoma.

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.

The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.